



"Challenges and solutions to conducting clinical research in rare diseases"

Peter A. Merkel, MD, MPH
Professor of Medicine and Epidemiology
University of Pennsylvania
Principal Investigator
Vasculitis Clinical Research Consortium







Peter A. Merkel, M.D., M.P.H. **Financial Disclosures**

Dr. Merkel has current or has had recent financial support for research, consultation, and/or educational activities from the following sources:

Consulting:

- Actelion
- Boston Pharm.
- ◆ Bristol-Myers Squibb → CaridianBCT
- ◆ ChemoCentryx
- Genzyme/Sanofi
- GlaxoSmithKline
- ◆ Genentech/Roche
- ◆ InflaRx
- Insmed

Research Support:

- Actelion

- Celgene
- ◆ ChemoCentryx
- ◆ Genentech/Roche
- ▲ GlaxoSmithKline
- Kypha
- ◆ MedImmune/AZ

Research Support:

- American College of Rheumatology
- ◆ Bristol-Myers Squibb ◆ European League Against Rheumatism
 - National Institutes of Health (NHLBI • NIAMS • NIAID • NCATS • ORDR)
 - US Food and Drug Administration
 - ◆ The Patient-Centered Outcomes Research Institute
 - The Vasculitis Foundation

Royalties:

UpToDate

Off-label use of various medications will be discussed in this presentation

Rare Diseases

- What is a rare disease?
 - A disease with a prevalence of <200,000 persons in USA
 - Estimated to be ~7000 rare diseases
 - US estimate: 25-30 million people with a rare disease (8-12% of US population)
- Increasing awareness of rare diseases by public via media, internet, advocacy/support groups
- Many major scientific breakthroughs have arisen stemming from investigation of rare diseases that often have impact on common disorders
- Rare disorders have fascinated physicians and nonphysicians for centuries

Why do we do rare diseases research?

- When you or a loved one are the patient with a rare disease, the disease is no longer rare
- When you have a patient with a rare disease, your ignorance will not help: become expert or refer
- People are drawn to rare disease research for the some of the same reasons others choose a research focus
 - Fascination with subject
 - Opportunity
 - Inspiration by patient/teacher

Some Joys & Challenges of Rare Disease Care and Research

- Nice to be an expert about things most people don't know about
- Nobody really knows what on earth you study or see clinically
- There are HUGE unanswered questions for rare diseases
- There are HUGE unanswered questions for rare diseases
- You can carve out your own niche when studying a rare disease
- You must carve out your own niche when studying a rare disease
- Often work in collaborative, multi-center research groups
- Markedly increased complexities with multi-center studies
- Face interesting and unique issues in dealing with rare diseases
- Still face the same challenges as studying common disorders

Bench to Bedside is a nice model...








Bedside to Bench is likely more productive and common (esp. for rare disease)







Bedside Bench is really a bidirectional process, especially for rare diseases



Rare Disease Research: Opportunities

- HUGE unanswered questions for rare diseases
- Potential to make a major impact on a clinically and scientifically underserved population
- The internet is now a key resource for rare disease research
 - Referrals/Recruitment
 - Networking
 - Conduct of research
- Increasing recognition in the scientific community and among funding agencies regarding the importance and benefits of research in rare diseases
- You can carve out your own niche when studying a rare disease

Rare Disease Research: Challenges

- Sample sizes and recruitment:
 - these are rare diseases!
- IRB/HIPPA:
 - must protect privacy
- Funding:
 - these markets are, by definition, small
- Career development
 - mentors/models are harder to find
 - obtain protected time while still a clinical expert
- Still have all the usual challenges of a career in academic medicine...

Solutions: Clinical Piece

- Don't forget the patient
 - Listen to your patients-they will teach you
- Master the disease
 - Become a student of the disease
- Join/engage with patient advocacy groups
 - Become a citizen of the disease
- Promote your expertise (if it is real)
- Protect your time and focus (well, try)

Solutions: Science Piece

- Do good science
 - -There is a limit to compromising due to small sample sizes
 - -"Pilot" does not mean "less than good"
 - -Be realistic
- Look to "borrow" ideas and approaches from other fields
 - Research approaches for related common diseases may be well-developed and adaptable
- Work collaboratively—Network, including internationally
 - -Face the challenges to sharing credit among many people

Solutions: Funding Piece

- Don't believe the hype
 - There IS funding for research (in US)
 - The NIH budget doubled in the past 25 years
 - Shift to more collaborative and multi-specialty approaches
 - Need to work with the new funding realities
 - Take advantage of opportunities and Grants:
 - Federal: NIH, FDA, PCORI, VA, DOD, Other
 - Non-federal funding: Industry, Patient Groups, Institutional, Others
 - Leverage resources (not just \$)
 - Clinical Trials
 - Existing Datasets/Repositories/Cohorts
 - Collaborations
 - Core Resources: Institutional, National/International
 - Expand the focus of your inquiry
 - E.g.: Not just vasculitis but vascular inflammation in general
 - Keep your eyes open

NIH Numerology, Alphabet Soup, and Nomenclature

- •K08
- •K12
- •K23
- •K24
- •K30
- •T32
- •NRSA (F32)
- Other

- •R01
- •R13
- •R21
- •R01
- •U01
- •U34
- •U54
- Other

- Grants
- Contracts
- Cooperative agreements
- Networks
- SBIRs
- •ISTs
- RFAs
- RFPs
- Other

Solutions: Career Piece

- Find a good mentor or at least a supporter
- Don't be afraid of learning new research skills
- Create the right environment for research
 - Ask for the resources you need
- Contribute and receive benefit from collaborations
 - Be a team player but don't just be a follower

Successful Rare Disease Research is <u>Clearly</u> Possible!

- The posters at this meeting testify to this fact
- As with any type of research, challenges exist but solutions are available

This is an excellent time to engage in clinical research in rare diseases

Multi-center research collaborations are extremely helpful for conducting high-quality, high-impact clinical research in rare diseases

Research Networks for Rare Diseases

• Pros:

- > Reduce start-up time/costs-leverage resources
 - Centers, personnel, systems already in place
 - Forms/data entry/CRFs, training, communications
- Established cohorts and recruitment streams
- ➤ Share workload & credit → trust
- Combine expertise
- > Recycle experience
- Look good to funding agencies/sponsors

Research Networks for Rare Diseases

• Pros:

- > Reduce start-up time/costs-leverage resources
 - Centers, personnel, systems already in place
 - •Forms/data entry/CRFs, training, communications
- > Established cohorts and recruitment streams
- > Share workload & credit > trust
- Combine expertise
- > Recycle experience
- Look good to funding agencies/sponsors

• Cons:

- Must maintain infrastructure
- ➤ Need to avoid stagnation → add flexibility
- > Require work to maintain cohesiveness
- > Takes a long time until productive
- > Many, many authors share credit-problem for jr. faculty



The Rare Diseases Clinical Research Network (RDCRN)





Goals of the RDCRN

- Facilitate clinical research by:
 - Creation of Consortia focused on related diseases
 - Cost-sharing research infrastructures
 - Establishing uniform protocols for data collection
 - Making meaningful large-scale studies possible
 - Longitudinal cohorts, pilot projects, and randomized trials
- Directly engage patients and their advocates
- Train new investigators in rare diseases research



History of the RDCRN

- Established by the Office of Rare Diseases Research
- Started in 2003--currently in 3rd 5 year cycle
 - 1st cycle (10 Consortia) supported by ORDR, NCRR, NINDS, NIAMS, NICHD, NHLBI, NIDDK
 - 2nd cycle (19 Consortia) supported by ORDR, NINDS, NIAMS, NICHD, NHLBI, NIDDK, NIAID, NIDCR, NCI
 - 3rd cycle (22 Consortia) supported by ORDR, NCATS, NINDS, NIAMS, NICHD, NHLBI, NIDDK, NIAID, NIDCR, NCI, NIMH, ODS
- Currently involves 267 institutions world-wide
- Collectively studying >200 diseases
- 46,760 patients enrolled in studies (during all 3 grant cycles)

DHHS-NIH ORDR, NINDS, NIAMS, NICHD, NHLBI, NIDDK, NIDCR, NIAID, NCI, NIMH

Coalition of Patient Advocacy Groups (CPAG) **Dystonia** Coalition

Consortium of Eosinophilic Gastrointestinal Disease Researchers

> **North America Mitochondrial Diseases Consortium**

Genetic Disorders of Mucociliary Clearance Consortium

Porphyria Rare Disease **Clinical Research Consortium**

Vasculitis Clinical Research Consortium

Brittle Bone Disease

Inherited Neuropathies Consortium

> **Development Synaptopathies** Consortium

Consortium

Clinical Research in ALS and **Related Disorders for Therapeutic Development**

National Institutes of Health

Collaborative Clinical Research

 Centralized Data Coordination and Technology Development

Public Resources and Education

Training

Primary Immune Deficiency Treatment Consortium

Advancing Research & Treatment for

Frontotemporal Lobar Degeneration

The Data Management and **Coordinating Center**

> **Rare Kidney Stone Consortium**

Nephrotic Syndrome Rare Disease Clinical **Research Network**

Chronic Graft Versus Host Disease Consortium

Rare Lung Disease Consortium

Rett Syndrome, MECP2 Duplications, and Rett-related Disorders Consortium

Brain Vascular Malformation Consortium

Sterol and Isoprenoid **Diseases Consortium**


Autonomic Rare Diseases Clinical Research Consortium

Lysosomal **Disease Network**

Consortium

Urea Cycle Disorders

<u>DHHS-NIH</u> ORDR, NCATS, NINDS, NIAMS, NICHD, NHLBI, NIDDK, NIDCR, NIAID, NCI, NIMH, ODS



Coalition of Patient Advocacy Groups (CPAG)



Primary Immune Deficiency
Treatment Consortium









Developmental Synaptopathies Consortium











- Collaborative Clinical Research
- Public Resources and Education
- Centralized Data Coordination
 and Technology Development
 - Training





The Data Management and Coordinating Center



Genetic Disorders of Mucociliary Clearance Consortium














Autonomic Disorders Consortium



Rare Diseases Clinical Research Network (RDCRN)



Autonomic Disorders Consortium

Brain Vascular Malformation Consortium

Brittle Bone Disorders Consortium

Chronic Graft Versus Host Disease Consortium

Clinical Research in ALS and Related Disorders for Therapeutic Development Consortium

Consortium of Eosinophilic
Gastrointestinal Disease Researchers

Development Synaptopathies Consortium

Dystonia Coalition

Advancing Research & Treatment for Frontotemporal Lobar Degeneration

Genetic Disorders of Mucociliary
Clearance Consortium

Inherited Neuropathies Consortium

Lysosomal Disease Network

Nephrotic Syndrome Study Network

North American Mitochondrial Disease Consortium

Porphyrias Consortium

Primary Immune Deficiency
Treatment Consortium

Rare Kidney Stone Consortium

Rare Lung Diseases Consortium Rett Syndrome, MECP2 Duplications, and Rett-related Disorders Consortium

Sterol and Isoprenoid
Disorders Consortium

Urea Cycle Disorders
Consortium

Vasculitis Clinical Research
Consortium

Data Management and Coordinating Center (DMCC)

Coalition of Patient Advocacy Groups (CPAG) (>95 PAGs)

This is an excellent time to engage in clinical research in rare diseases

IT CAN BE DONE!